Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-VTE-I: REGN9933 for VTE Prevention after TKA
NCT05618808Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of amrecibart in venous thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Started May 2023; status: completed.
02
Drugs
amrecibart
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05618808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618808.